EAACI Congress 2023
BackDupilumab is effective in children (6–11 years) with moderate-to-severe asthma and high eosinophils at baseline
Friday 09 Jun, 13:39 PM -
13:51 PM CEST
Hall Y 03+04
ORAL Session